Coverage of Preferential Population Groups for Antihypertensive Medicines in Almaty, Kazakhstan

Datos Bibliográficos

ID7759863
AutoresD Zh Abuov, Д Ж Абуов (Kazakhstan Medical University), A M Grjibovski, Andrej М Grjibovski (0000-0002-5464-0498, Norwegian Institute of Public Health), Zh A Kalmantaeva, Ж А Калмантаева (Kazakhstan Medical University), E S Stepkina, Е С Степкина (Kazakhstan Medical University), A Sh Rustemova, А Ш Рустемова (Kazakhstan Medical University)
Año2014
Volumen21
Número12
Páginas21-25
Fecha de publicación2014-12-15
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaEkologiya Cheloveka (Human Ecology (JOURNAL)
Identificadores de la revistaISSN: 1728-0869 • E-ISSN: 2949-1444
EditorialECO-Vector LLC (PUBLISHER • RU)
DOI10.17816/humeco17176
OpenAlexW2613197100
IdiomaEN
Referencias citadas1

The aim of this descriptive study was to assess the coverage of preferential population groups for antihypertensive medicines in Almaty, the former capital of Kazakhstan. We present the data on the coverage of preferential population groups for the period from 2008 through 2012. The absolute number of residents who were covered for antihypertensive medicines increased from 31814 to 73518. Financial resources allocated by the state to cover the privileged population of Almaty for antihypertensive medicines increased from 28 188 714 KZT (233 423, 86 USD) in 2008 to 223 050 004 KZT (1 492 720,67 USD) in 2012 which corresponds to per capita increase from 7,34 USD in 2008 to 20,3 USD in 2012. The next step which we plan to make in a few years from now is to assess whether these measures has led to decrease in mortality from hypertension and from diseases of circulatory system in general

Defined daily dose · Environmental health · Per capita · Population · Blood Pressure and Hypertension Studies · Global Health Care Issues · Healthcare Systems and Reforms · Medicine · Pharmacology